Company intelligence / Profile preview

CellRev

Newcastle upon Tyne, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

CellRev developed bioprocessing and enzymatic technologies to enhance cell culture efficiency and scalability, particularly for cell-based therapies and lab-grown meat. Their AggreGuard™ platform demonstrated the ability to reduce cell-to-cell adhesion in suspension cultures, leading to improved cell viability and productivity in model systems[2]. Despite technical innovations, the company entered administration in August 2025 due to funding challenges[4].

Therapeutic areas: HematologyOther
Modalities: Bioprocessing solutionEnzymatic solutionCell culture technologyCell therapy
Industry: Non-Drug Biotech

Partnerships

BSF Enterprise (previously partnered for Cultivated Meat Technologies Limited, which was dissolved after BSF withdrew)

Beyond the preview

Go deeper on CellRev.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellRev.

Explore the full profile